I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Dan Paterson Biography and Net Worth

COO of Verastem

Mr Paterson joined Verastem Oncology in 2011 and has served as its Chief Operating Officer since 2014. He has more than 30 years of experience at healthcare and biotechnology companies, including leadership roles as Chief Business Officer (CBO), Chief Operating Officer (COO) and Chief Executive Officer (CEO), with specific expertise in oncology drug and diagnostic product development, business development, and launch planning. Mr Paterson was the co-founder and COO of On-Q-ity, a developer of technology to capture and analyze circulating tumor cells, and the founding CEO of The DNA Repair Company (merged to form On-Q-ity), which developed oncology-focused molecular diagnostics. Prior to that, Mr Paterson was Head of Global Strategy for Specialty Market and Patient-Level Data at IMS Health, after playing a key role in the acquisition of PharMetrics by IMS Health as VP, Marketing and Corporate Development. While at PharMetrics, Mr Paterson led the development of an innovative suite of pharmaceutical product launch tools that became the basis of the company’s product line. Mr Paterson holds a BA in biology from Boston University, and attended the Northeastern University Graduate Pharmacology program.

What is Dan Paterson's net worth?: The estimated net worth of Dan Paterson is at least $910,960.96 as of September 19th, 2024. Mr. Paterson owns 232,388 shares of Verastem stock worth more than $910,961 as of November 2nd. This net worth evaluation does not reflect any other assets that Mr. Paterson may own. Additionally, Mr. Paterson receives an annual salary of $697,980.00 as COO at Verastem. Learn More about Dan Paterson's net worth.
How old is Dan Paterson?: Mr. Paterson is currently 63 years old. There are 5 older executives and no younger executives at Verastem. The oldest executive at Verastem is Mr. Richard H. Aldrich M.B.A., Founder and Consultant, who is 70 years old. Learn More on Dan Paterson's age.
What is Dan Paterson's salary?: As the COO of Verastem, Inc., Mr. Paterson earns $697,980.00 per year. The highest earning executive at Verastem is Mr. Daniel Calkins, CFO and Principal Accounting & Financial Officer, who commands a salary of $1,420,000.00 per year. Learn More on Dan Paterson's salary.
How do I contact Dan Paterson?: The corporate mailing address for Mr. Paterson and other Verastem executives is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. Verastem can also be reached via phone at (781) 292-4200 and via email at [email protected]. Learn More on Dan Paterson's contact information.
Has Dan Paterson been buying or selling shares of Verastem?: Dan Paterson has not been actively trading shares of Verastem over the course of the past ninety days. Most recently, Dan Paterson sold 184 shares of the business's stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $2.79, for a transaction totalling $513.36. Following the completion of the sale, the chief executive officer now directly owns 232,388 shares of the company's stock, valued at $648,362.52. Learn More on Dan Paterson's trading history.
Who are Verastem's active insiders?: Verastem's insider roster includes Robert Gagnon (CFO), Dan Paterson (COO), and Brian Stuglik (CEO). Learn More on Verastem's active insiders.
Are insiders buying or selling shares of Verastem?: In the last twelve months, insiders at the biopharmaceutical company sold shares 18 times. They sold a total of 10,882 shares worth more than $113,401.06. The most recent insider tranaction occured on October, 7th when CFO Daniel Calkins sold 6 shares worth more than $17.16. Insiders at Verastem own 2.2% of the company. Learn More about insider trades at Verastem.
Information on this page was last updated on 10/7/2024.

Dan Paterson Insider Trading History at Verastem

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/19/2024	Sell	184	$2.79	$513.36	232,388
3/18/2024	Sell	244	$10.71	$2,613.24	86,672
12/18/2023	Sell	244	$7.64	$1,864.16	87,099
9/18/2023	Sell	240	$9.91	$2,378.40	87,526
6/20/2023	Sell	183	$10.30	$1,884.90	37,766
6/16/2023	Sell	244	$9.92	$2,420.48	37,949
3/20/2023	Sell	194	$5.16	$1,001.04	38,195
3/16/2023	Sell	261	$4.80	$1,252.80	38,390
9/19/2022	Sell	232	$13.56	$3,145.92	40,204
6/21/2022	Sell	225	$13.68	$3,078.00	40,437
3/21/2022	Sell	234	$15.24	$3,566.16
12/20/2021	Sell	916	$27.24	$24,951.84
9/27/2018	Buy	166	$84.36	$14,003.76	1,590
6/18/2015	Buy	83	$96.60	$8,017.80
12/19/2014	Buy	166	$102.24	$16,971.84
5/15/2014	Buy	83	$89.64	$7,440.12	4,845

Dan Paterson Buying and Selling Activity at Verastem

Verastem Company Overview

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Today's Range

Now: $3.92

$3.77

$4.00

50 Day Range

MA: $2.90

$2.40

$3.92

2 Week Range

Now: $3.92

$2.10

$14.22

Volume

721,205 shs

Average Volume

1,127,837 shs

Market Capitalization

$157.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14

True paradigm shift

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Dan Paterson Biography and Net Worth

What is Dan Paterson's net worth?

How old is Dan Paterson?

What is Dan Paterson's salary?

How do I contact Dan Paterson?

Has Dan Paterson been buying or selling shares of Verastem?

Who are Verastem's active insiders?

Are insiders buying or selling shares of Verastem?